Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02203084
Other study ID # H14-01278
Secondary ID
Status Completed
Phase N/A
First received July 25, 2014
Last updated September 19, 2017
Start date September 1, 2014
Est. completion date August 1, 2017

Study information

Verified date September 2017
Source University of British Columbia
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Anyone who practices clinical medicine will understand that socially disadvantaged children will have worse health outcomes, no matter what the underlying condition might be. There is limited prospective data on the effects of social deprivation on children in BC and there is none concerning the effects of social deprivation on children with chronic diseases. In order to generate relevant data for those who manage children with chronic diseases in BC, the investigators wish to perform an observational study of the relationship between questionnaire-derived social variables and measured outcomes in children with cystic fibrosis, type 1 diabetes, and chronic kidney disease.

Our working hypothesis is that there is an association between social determinants of health (income, education, race) and health outcomes in children with cystic fibrosis, type 1 diabetes and chronic renal failure, that is independent of access to health care (assessed by distance to nearest specialty clinic and number of clinic visits in the last year).


Description:

1. Cystic fibrosis (CF). Cystic fibrosis is a genetic condition that causes slowly progressive lung disease. It occurs in people of all social class so the disease itself is independent of social factors. There is considerable variation in the outcome of CF in different children. There are many potential causes for these differences but the available literature would suggest that a significant part of this variability is due to social factors. While there are no prospective clinical studies, the limited information from database reviews suggest that socially deprived children have significantly worse outcomes. In the US, children living in poverty are twice as likely to be underweight and over three times more likely to die (25). UK data is similar - disadvantaged children have worse growth parameters and lower lung function compared to richer children (26).

2. Type 1 diabetes (T1D). Type 1 diabetes is a multi-factorial disease. It is not an autosomal recessive disease like CF but genetic predisposition can be one of its predisposing features. As with the data on CF, socio-economic deprivation has been shown to have a significant adverse effect on outcome in type 1 diabetes. In the US, glycemic control amongst young adults was significantly worse amongst disadvantaged young adults (27). A retrospective review of New Zealand children with type 1 diabetes also showed that poor socio-economic status and Polynesian ethnicity were significantly associated with poor glycemic control and long term complications (28).

3. Chronic kidney disease (CKD). Chronic kidney disease may be due to congenital, acquired, or hereditary causes. Within all these groups, socioeconomic status, gender, and race may influence disease progression and outcomes. It has been shown in children with chronic kidney disease, primarily from the United States, that it was more common in low- and middle- income families to have an abnormal birth history such as prematurity, low birth weight or small for age which predisposes to the development of renal disease (29). In addition, blood pressure control and height deficits improve faster in children of families with higher income. In Canada, Aboriginals have a higher prevalence of severe chronic kidney disease and a 77% increased mortality risk (30,31) and a lower likelihood of nephrology clinic visits (32). Aboriginal children and young adults with chronic kidney disease are more likely to have glomerulonephritis as a cause of kidney disease compared to Caucasians and are more likely to reach end stage renal disease (33). In contrast, lower mortality risks are seen in East Asian and Indo Asian Canadian adults starting dialysis (34). There is still much to be studied on the influence of these various factors in renal health and disease.

STUDY DESIGN.

1. Study Objective. We wish to determine the influence of education, income, race and access to health care upon health outcomes in children with chronic diseases in British Columbia.

2. Justification. While the effects of social deprivation on health outcomes are commonly discussed, it is surprising how little prospective research there is to quantify the adverse effects of social inequity. There is limited prospective data on the effects of social deprivation on children in BC and there is none concerning the effects of social deprivation on children with chronic diseases. In order to generate firm data relevant for those who manage children with chronic diseases in BC, we wish to perform a cross sectional observational study of the relationship between social variables and outcome in children with cystic fibrosis, type 1 diabetes and chronic kidney disease.

3. General design. All families in the three clinics will initially be informed of the study by letter. When the child is due for regular follow-up assessment, the parents will be approached during the clinic visit and invited to join the study. Their participation will only involve the completion of a questionnaire. The research assistant will collect the data at interview and will subsequently (with parental permission) retrieve laboratory results from records of previous clinic visits to assess measured health trends over time. The study protocol does not add any further investigations other than the questionnaire. Apart from the variable time needed for parent information and consent, the questionnaire itself will require no more than about 30 minutes to complete.

4. Questionnaire. We will use a socio-economic assessment questions that we are already using in our study of quality of life in parents caring for children needing home ventilation. It is a conventional form assessing education level, employment, income, partnership status and ethnicity. This last is very important because of the poorer health outcomes already known to be associated with Aboriginal background. The proxy for access to health care will be distance to the main specialty clinic and number of visits in the last year.

5. Analysis. The relationship between socio-economic variables plus ethnicity and outcome will be examined using multiple linear regression analysis. In the absence of relevant literature, there are too many unknowns to allow any reliable form of power analysis or patient number calculation to be performed. One accepted 'rule of thumb' is that there should be at least 10 patients for each predictive variable in multiple linear regression analysis. We will concentrate on 6 to 8 of the main social factors and will try to enroll over 100 patients within each sub-specialty - enough to ensure 15 to 20 patient outcomes for each variable.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date August 1, 2017
Est. primary completion date June 1, 2017
Accepts healthy volunteers No
Gender All
Age group 1 Year to 17 Years
Eligibility Inclusion Criteria:

- Any individual who attends British Columbia Children's Hospital Ambulatory clinics in the following areas: cystic fibrosis, chronic kidney disease, or type 1 diabetes

Exclusion Criteria:

- Refusal to join the study

- Acute Medical Instability

Study Design


Intervention

Other:
Social Determinants Questionnaire
The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.

Locations

Country Name City State
Canada BC's Children's Hospital Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
University of British Columbia

Country where clinical trial is conducted

Canada, 

References & Publications (10)

Bulloch B, Postl BD, Ogborn MR. Excess prevalence of non diabetic renal disease in native American children in Manitoba. Pediatr Nephrol. 1996 Dec;10(6):702-4. — View Citation

Carter PJ, Cutfield WS, Hofman PL, Gunn AJ, Wilson DA, Reed PW, Jefferies C. Ethnicity and social deprivation independently influence metabolic control in children with type 1 diabetes. Diabetologia. 2008 Oct;51(10):1835-42. doi: 10.1007/s00125-008-1106-9. Epub 2008 Aug 5. — View Citation

Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Ahmed S, Hemmelgarn BR; Alberta Kidney Disease Network. Access to health care among status Aboriginal people with chronic kidney disease. CMAJ. 2008 Nov 4;179(10):1007-12. doi: 10.1503/cmaj.080063. — View Citation

Gao S, Manns BJ, Culleton BF, Tonelli M, Quan H, Crowshoe L, Ghali WA, Svenson LW, Hemmelgarn BR; Alberta Kidney Disease Network. Prevalence of chronic kidney disease and survival among aboriginal people. J Am Soc Nephrol. 2007 Nov;18(11):2953-9. Epub 2007 Oct 17. — View Citation

Hidalgo G, Ng DK, Moxey-Mims M, Minnick ML, Blydt-Hansen T, Warady BA, Furth SL. Association of income level with kidney disease severity and progression among children and adolescents with CKD: a report from the Chronic Kidney Disease in Children (CKiD) Study. Am J Kidney Dis. 2013 Dec;62(6):1087-94. doi: 10.1053/j.ajkd.2013.06.013. Epub 2013 Aug 7. — View Citation

Samuel SM, Foster BJ, Hemmelgarn BR, Nettel-Aguirre A, Crowshoe L, Alexander RT, Soo A, Tonelli MA; Pediatric Renal Outcomes Canada Group. Incidence and causes of end-stage renal disease among Aboriginal children and young adults. CMAJ. 2012 Oct 2;184(14):E758-64. doi: 10.1503/cmaj.120427. Epub 2012 Aug 27. — View Citation

Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med. 2001 May;163(6):1331-7. — View Citation

Secrest AM, Costacou T, Gutelius B, Miller RG, Songer TJ, Orchard TJ. Associations between socioeconomic status and major complications in type 1 diabetes: the Pittsburgh epidemiology of diabetes complication (EDC) Study. Ann Epidemiol. 2011 May;21(5):374-81. doi: 10.1016/j.annepidem.2011.02.007. — View Citation

Taylor-Robinson DC, Smyth RL, Diggle PJ, Whitehead M. The effect of social deprivation on clinical outcomes and the use of treatments in the UK cystic fibrosis population: a longitudinal study. Lancet Respir Med. 2013 Apr;1(2):121-8. doi: 10.1016/S2213-2600(13)70002-X. Epub 2013 Jan 30. — View Citation

Yeates K. Health disparities in renal disease in Canada. Semin Nephrol. 2010 Jan;30(1):12-8. doi: 10.1016/j.semnephrol.2009.10.014. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Level of glycosylated hemoglobin (HbA1C) The level of glycosylated hemoglobin (HbA1C) is the conventional measure of glycemic control and will be used to assess the diabetic group. Data is measured every 3-6 months and will be collected from previous clinic visits. Measurements performed routinely at clinic visits. The monitoring results will be recorded but the study does not require or involve any testing other than tests associated with routine clinical practice. 1 year
Primary Height/weight Height/weight used to assess cystic fibrosis patients. Measurements performed routinely at clinic visits. The monitoring results will be recorded but the study does not require or involve any testing other than tests associated with routine clinical practice. 1 year
Primary Lung Function Tests Lung function tests used to assess cystic fibrosis patients. Measurements performed routinely at clinic visits. The monitoring results will be recorded but the study does not require or involve any testing other than tests associated with routine clinical practice. 1 year
Primary Glomerular filtration rate (GFR) GFR used to assess renal failure patients. Measurements performed routinely at clinic visits. The monitoring results will be recorded but the study does not require or involve any testing other than tests associated with routine clinical practice. 1 year
Primary Albumin/creatinine ratio Albumin/creatinine ratio used to assess renal failure patients. Measurements performed routinely at clinic visits. The monitoring results will be recorded but the study does not require or involve any testing other than tests associated with routine clinical practice. 1 year
See also
  Status Clinical Trial Phase
Completed NCT04696198 - Thoracic Mobility in Cystic Fibrosis Care N/A
Completed NCT00803205 - Study of Ataluren (PTC124™) in Cystic Fibrosis Phase 3
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03601637 - Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del Phase 3
Terminated NCT02769637 - Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
Recruiting NCT06032273 - Lung Transplant READY CF 2: CARING CF Ancillary RCT N/A
Recruiting NCT06030206 - Lung Transplant READY CF 2: A Multi-site RCT N/A
Recruiting NCT06012084 - The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis N/A
Recruiting NCT06088485 - The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
Recruiting NCT05392855 - Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF) N/A
Recruiting NCT04056702 - Impact of Triple Combination CFTR Therapy on Sinus Disease.
Recruiting NCT04039087 - Sildenafil Exercise: Role of PDE5 Inhibition Phase 2/Phase 3
Completed NCT04058548 - Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation N/A
Completed NCT04038710 - Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Recruiting NCT03506061 - Trikafta in Cystic Fibrosis Patients Phase 2
Completed NCT03566550 - Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
Recruiting NCT04828382 - Prospective Study of Pregnancy in Women With Cystic Fibrosis
Completed NCT04568980 - Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
Recruiting NCT04010253 - Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis N/A